| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 50090-7933-06 | 50090-7933 | PREDNISONE | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 24, 2026 | In Use | |
| 50090-7935-00 | 50090-7935 | PREDNISONE | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 10, 2026 | In Use | |
| 50268-0032-12 | 50268-0032 | Abiraterone Acetate | Abiraterone Acetate | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | May 4, 2026 | In Use | |
| 50881-0011-08 | 50881-0011 | Ruxolitinib | JAKAFI XR | 11.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | May 1, 2026 | In Use | |
| 50881-0022-08 | 50881-0022 | Ruxolitinib | JAKAFI XR | 22.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | May 1, 2026 | In Use | |
| 50881-0033-08 | 50881-0033 | ruxolitinib | JAKAFI XR | 33.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | May 1, 2026 | In Use | |
| 50881-0044-08 | 50881-0044 | Ruxolitinib | JAKAFI XR | 44.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | May 1, 2026 | In Use | |
| 82094-0404-50 | 82094-0404 | Methylprednisolone | Methylprednisolone Sodium Succinate | 1.0 g/16mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Apr 20, 2021 | In Use | |
| 60505-4499-02 | 60505-4499 | Pomalidomide | Pomalidomide | 3.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 11, 2026 | In Use | |
| 50881-0055-08 | 50881-0055 | Ruxolitinib | JAKAFI XR | 55.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | May 1, 2026 | In Use | |
| 73462-0101-01 | 73462-0101 | Trilaciclib | Cosela | 300.0 mg/20mL | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Intravenous | Feb 12, 2021 | Dec 31, 2028 | In Use |
| 55154-2581-00 | 55154-2581 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 30, 2026 | In Use | |
| 00703-5657-01 | 00703-5657 | Etoposide | Toposar | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | May 1, 1997 | Aug 31, 2022 | In Use |
| 60505-4500-02 | 60505-4500 | Pomalidomide | Pomalidomide | 4.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 11, 2026 | In Use | |
| 81298-5785-03 | 81298-5785 | Triamcinolone Acetonide | Triamcinolone Acetonide | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-arterial, Intramuscular | May 2, 2022 | In Use | |
| 43066-0001-01 | 43066-0001 | docetaxel | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb 19, 2018 | In Use | |
| 68071-3721-01 | 68071-3721 | PREDNISONE | PREDNISONE | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec 19, 2024 | In Use | |
| 81927-0204-01 | 81927-0204 | Methotrexate | JYLAMVO | 2.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Dec 15, 2023 | In Use | |
| 61786-0027-57 | 61786-0027 | Methylprednisolone Acetate | Depo-Medrol | 80.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intralesional, Intramuscular, Intrasynovial, Soft Tissue | Sep 11, 2014 | Sep 27, 2018 | In Use |
| 55513-0160-01 | 55513-0160 | Blinatumomab | Blincyto | Immunotherapy | Monoclonal Antibody | CD3 (T cells) and CD19 (B cells) | Intravenous | Dec 18, 2014 | In Use | ||
| 55513-0160-21 | 55513-0160 | Blinatumomab | Blincyto | Immunotherapy | Monoclonal Antibody | CD3 (T cells) and CD19 (B cells) | Intravenous | Apr 30, 2026 | In Use | ||
| 65162-0805-14 | 65162-0805 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Apr 3, 2015 | In Use | |
| 65862-0188-10 | 65862-0188 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 31, 2007 | In Use | |
| 55513-0099-01 | 55513-0099 | Pegfilgrastim | Neulasta | 4.0 mg/.4mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Mar 31, 2026 | In Use | |
| 72266-0125-01 | 72266-0125 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Feb 15, 2019 | In Use |
Found 12393 results — Export these results
Home